Helix Acquisition Corp. II operates as a blank check company. The company is headquartered in Boston, Massachusetts. The company went IPO on 2024-02-09. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company has entered into a business combination agreement with TheRas, Inc., doing business as BridgeBio Oncology Therapeutics. Upon closing of the transaction, the combined company will be renamed BridgeBio Oncology Therapeutics, Inc.
Follow-Up Questions
What is BridgeBio Oncology Therapeutics Inc (BBOT)'s P/E Ratio?
The P/E ratio of BridgeBio Oncology Therapeutics Inc is 118.9769
What is the price performance of BBOT stock?
The current price of BBOT is $10.82, it has decreased 0% in the last trading day.
What are the primary business themes or industries for BridgeBio Oncology Therapeutics Inc?
BridgeBio Oncology Therapeutics Inc belongs to N/A industry and the sector is N/A
What is BridgeBio Oncology Therapeutics Inc market cap?
BridgeBio Oncology Therapeutics Inc's current market cap is $856.9M
Is BridgeBio Oncology Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for BridgeBio Oncology Therapeutics Inc, including 3 strong buy, 4 buy, 1 hold, 0 sell, and 3 strong sell
